Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310.
Journal: The New England journal of medicine
Published: August 28, 2026
Ethical and Regulatory Considerations for Developing Gene Therapies Involving Genome Editing.
Journal: Human gene therapy
Published: March 28, 2026
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.
Journal: The New England journal of medicine
Published: November 10, 2025
A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule.
Journal: The European respiratory journal
Published: July 26, 2024
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age.
Journal: The New England journal of medicine
Published: June 26, 2024
Sclerokeratouveitis presumed to be associated with durvalumab treatment.
Journal: Journal francais d'ophtalmologie
Published: June 17, 2024
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.
Journal: The New England journal of medicine
Published: May 20, 2024
Bilateral conjunctival and eyelid lesions along generalized skin rash in a case of Mpox.
Journal: Journal francais d'ophtalmologie
Published: March 23, 2024
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
Journal: The New England journal of medicine
Published: October 04, 2023
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
Journal: Journal of the American Academy of Dermatology
Published: October 03, 2023
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
Journal: The Journal of allergy and clinical immunology
Published: October 02, 2023
Last Updated: 09/26/2026